Last reviewed · How we verify

Paracetamol +caudal ropivacaine

Aga Khan University · FDA-approved active Small molecule

Paracetamol reduces pain and fever through central inhibition of prostaglandin synthesis, while caudal ropivacaine provides local anesthetic blockade of nerve conduction in the sacral region.

Paracetamol reduces pain and fever through central inhibition of prostaglandin synthesis, while caudal ropivacaine provides local anesthetic blockade of nerve conduction in the sacral region. Used for Perioperative pain management in pediatric and adult patients undergoing lower abdominal, pelvic, or lower limb surgery, Acute postoperative pain relief.

At a glance

Generic nameParacetamol +caudal ropivacaine
SponsorAga Khan University
Drug classAnalgesic combination (systemic + local anesthetic)
TargetCOX inhibition (paracetamol); voltage-gated sodium channels (ropivacaine)
ModalitySmall molecule
Therapeutic areaPain Management / Anesthesia
PhaseFDA-approved

Mechanism of action

This is a combination therapy: paracetamol (acetaminophen) acts as a systemic analgesic and antipyretic by inhibiting cyclooxygenase enzymes in the central nervous system. Caudal ropivacaine is a local anesthetic administered via caudal epidural injection that blocks sodium channels in nerve fibers, providing regional anesthesia and analgesia in the lower body and pelvic region. Together, they provide multimodal pain control for perioperative or acute pain management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results